MHAA 4549A

Drug Profile

MHAA 4549A

Alternative Names: MHAA-4549A; RG 7745

Latest Information Update: 19 Sep 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Genentech
  • Class Antivirals; Monoclonal antibodies
  • Mechanism of Action Influenza virus haemagglutinin glycoprotein inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Influenza A virus infections

Most Recent Events

  • 23 May 2017 Genentech completes a phase II trial in Influenza-A virus infections (Combination therapy) in Belgium, Brazil, Bulgaria, Canada, Chile, Czech Republic, France, Germany, Hong Kong, Hungary, Italy, Netherlands, New Zealand, Peru, Poland, South Korea, Spain, Sweden and United Kingdom, Taiwan, Ukraine, Russia, South Africa, Mexico, Israel (NCT02293863)
  • 01 Mar 2016 Phase-II clinical trials in Influenza-A virus infections (Monotherapy) in USA (IV) (NCT02623322)
  • 10 Dec 2015 Genentech plans a phase II trial for Influenza-A virus (Monotherapy) in USA (IV) (NCT02623322)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top